The yeast protein Ubx4p contributes to mitochondrial respiration and lithium–galactose–mediated activation of the unfolded protein response

Received for publication, October 9, 2019, and in revised form, January 22, 2020. Published, Papers in Press, January 29, 2020, DOI 10.1074/jbc.RA119.011271

Evandro A. De-Souza, Felipe S. A. Pimentel, Ana Luiza F. V. De-Queiroz, Henrique Camara, Mikaela L. Felix-Formiga, Caio M. Machado, Silas Pinto, Antonio Galina, Marcelo A. Mori, Monica Montero-Lomeli, and Claudio A. Masuda

From the Programa de Biologia Molecular e Biotecnologia and the Programa de Bioquímica e Biofísica Celular, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil and the Department of Biochemistry and Tissue Biology, Instituto de Biologia, Universidade Estadual de Campinas, Campinas SP, 13083-970, Brazil

Edited by Ursula Jakob

In the presence of galactose, lithium ions activate the unfolded protein response (UPR) by inhibiting phosphoglucomutase activity and causing the accumulation of galactose-related metabolites, including galactose-1-phosphate. These metabolites also accumulate in humans who have the disease classic galactosemia. Here, we demonstrate that Saccharomyces cerevisiae yeast strains harboring a deletion of UBX4, a gene encoding a partner of Cdc48p in the endoplasmic reticulum–associated degradation (ERAD) pathway, exhibit delayed UPR activation after lithium and galactose exposure because the deletion decreases galactose-1-phosphate levels. The delay in UPR activation did not occur in yeast strains in which key ERAD or pro teaseal pathway genes had been disrupted, indicating that the ubx4Δ phenotype is ERAD-independent. We also observed that the ubx4Δ strain displays decreased oxygen consumption. The inhibition of mitochondrial respiration was sufficient to diminish galactose-1-phosphate levels and, consequently, affects UPR activation. Finally, we show that the deletion of the AMP-activated protein kinase ortholog–encoding gene SNF1 can restore the oxygen consumption rate in ubx4Δ strain, thereby reestablishing galactose metabolism, UPR activation, and cellular adaption to lithium–galactose challenge. Our results indicate a role for Ubx4p in yeast mitochondrial function and highlight that mitochondrial and endoplasmic reticulum functions are intertwined through galactose metabolism. These findings also shed new light on the mechanisms of lithium action and on the pathophysiology of galactosemia.

Lithium is one of the most common drugs used in the treatment of bipolar disorder patients. The molecular mechanisms of lithium action are not fully elucidated, but evidence points to a role for lithium as a GSK-3β inhibitor, as an inducer of inositol depletion, among others hypotheses (1). Lithium is also capable of inhibiting the activity of the enzyme phosphoglucomutase because it competes with its cofactor magnesium (2). Because of this inhibition, cells treated with lithium in the presence of galactose accumulate toxic metabolites of the Leloir pathway in yeast (2–4) and human cells (5). Accumulation of intermediate metabolites of galactose metabolism such as galactose-1-phosphate also occurs in patients with classic galactosemia, an inborn error of metabolism caused by mutations in the GALT gene (6, 7). Yeast is a eukaryotic cell model commonly employed in studies to better understand human diseases because of its similarities with human metabolism and its vast toolkit for genetic manipulation (8). Yeast cells treated with lithium in the presence of galactose exhibit modifications in cellular homeostasis such as changes in glycogen, calcium, and phosphate levels and a metabolic shift from fermentation to respiration (3, 9–11). Another important feature of lithium/galactose treatment is the increase in endoplasmic reticulum (ER) stress and unfolded protein response (UPR), both in yeast and in human cells (3, 5). This UPR activation depends on the synthesis of galactose-1-phosphate and also occurs in genetic models of classic galactosemia (3, 12, 13).

The ER is an organelle in which protein folding, glycosylation, and lipid synthesis take place. In yeast, during ER stress conditions, the communication between ER and nucleus is mediated by the conserved kinase/endonuclease protein Ire1p. This transmembrane protein, together with the tRNA ligase Tri1p, promotes the cytosolic splicing of the HAC1 gene (9–12). In human cells, this mechanism is also functional and occurs through the UPR acting on the XBP1 mRNA, which promotes the splicing of this mRNA and leads to the expression of proteins that help to adapt the cell to the ER stress condition (13). Another interesting aspect of lithium action is that it can modulate the function of different kinases and kinases-related enzymes such as GSK-3β and AMPK, whose activation is increased through lithium exposure (14–17). Lithium is also known to induce protein oxidation (18–20) and to inactivate the enzyme phosphoglucomutase (21), which competitively inhibits copper-dependent ionic functions, and it is possible that these functions help lithium to exert its therapeutic action (22).

This work was supported by research grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico, and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; by Fundação Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro Grants E-26/203.203/2015 (to M. M.-L.) and E-26/010.000837/2016 (to C. A. M.); and by Fundação de Amparo a Pesquisa do Estado do Rio de Janeiro Grants E-26/18148-9 (to M. A. M.). This work was also supported in part by Conselho Nacional de Desenvolvimento Científico e Tecnológico fellowships (to E. A. D.-S., F. S. A. P., A. L. F. V. D.-Q., C. M. M., and M. L. F.-F.), Fundação Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro fellowships E-26/200.790/2019 (to E. A. D.-S.), and Fundação de Amparo à Pesquisa do Estado de São Paulo fellowships 17/04377-2 (to S. P.) and 17/01339-2 (to H. C.). The authors declare that they have no conflicts of interest with the contents of this article.

This article contains Figs. S1–S6.

The abbreviations used are: ER, endoplasmic reticulum; UPR, unfolded protein response; ERAD, ER-associated degradation; AMPK, AMP-activated protein kinase; UBX, ubiquitin regulatory X; ANOVA, analysis of variance.
mRNA, which in turn codes for the transcription factor Hac1p (14, 15). Hac1p induces the activation of genes responsible for restoring ER homeostasis such as ER-resident chaperones (16). The Ire1/Hac1 branch of UPR is the only one present in yeast and is conserved from yeast to mammals (Ire1/Cui1p), being relevant to different diseases (17–20). A second way that cells can cope with ER stress is by alleviating proteotoxicity through the ER-associated protein degradation (ERAD) pathway. ER-localized misfolded proteins retrotranslocate to the cytosol, where they are ubiquitinated and degraded by the proteasome (21). In this work, we demonstrate the function of Ubx4p (Cui1p), a Cdc48p protein adaptor in the ERAD pathway (22, 23), on the cellular adaption to lithium and galactose toxicity. Ubx4p contains a ubiquitin regulatory X (UBX) domain that mediates physical interaction with Cdc48p (24) and an ubiquitin-like domain that is commonly found in proteins that can interact and recruit proteasome (25). In fact, both UBX and ubiquitin-like domains are necessary for Ubx4p interaction with the proteasome (23). Ubx4p homolog in humans is called ASPL/TUG, a protein that interacts with p97/VCP (homolog of Cdc48 in mammals) (26). Importantly, the expression of ASPL/TUG in an ubx4Δ strain is capable of recovering the proteasome localization defect of this strain. ASPL/TUG in mammals can also bind to the GLUT4 (glucose transporter type 4) and control its translocation to the plasma membrane upon insulin stimulation (27–29).

Here we show a novel and ERAD-independent role for Ubx4p in controlling mitochondrial and galactose metabolism. Our data demonstrate that UBX4 deletion impairs mitochondrial respiration, which in turn affects galactose metabolism and activation of the UPR. For these reasons, ubx4Δ mutants are less tolerant to lithium/galactose.

**Results**

Based on a genetic screen to identify new regulators of UPR activation induced by lithium and galactose treatment, we identified that the deletion of the UBX4/YMR067C gene delays UPR activation (Fig. 1A). In this context, the inhibition of the UPR pathway (e.g. deletion of IRE1 or HAC1 genes) causes loss of cell viability (3). We did not observe the same for the ubx4Δ mutant, which remained viable after 24 h of treatment with lithium in the presence of galactose (Fig. 1B), probably because this strain can still fully activate UPR (as measured by HAC1 mRNA splicing) after 4 h of treatment. These results suggest that Ubx4p is not interfering directly with Ire1p activity. Accordingly, the deletion of UBX4 did not affect UPR activation by tunicamycin treatment (Fig. S1).
This raised the hypothesis that the deletion of **LIBX4** is delaying ER stress occurrence in a lithium–galactose–specific manner. As previously described by our group, UPR activation in models of galactosemia can be prevented by the deletion of yeast galactokinase **GAL1** (3), suggesting that the synthesis of galactose-1-phosphate is an essential event for the UPR activation in this condition. Although we did not observe differences in the expression of genes of Leloir pathway (**GAL1** and **GAL2**) (Fig. 1C), we measured the galactose and galactose-1-phosphate levels in the **ubx4Δ** mutant, and we observed an 82–85% decrease in galactose (Fig. 1D) and a 77–93% decrease in galactose-1-phosphate levels (Fig. 1E) when compared with a control strain, even without lithium. These results suggest that the delayed UPR activation in the **ubx4Δ** strain is due to the overall decreased levels of galactose-1-phosphate accumulated in this strain.

**Ubx4p** is known to participate in the ERAD pathway and to regulate proper proteasome localization (22, 23). Thus, we reasoned that mutations in other components of these pathways would also influence UPR activation in lithium/galactose-treated cells. Nonetheless, the deletion of **UBC7**, a central effector of ERAD pathway (21, 30), or the deletion of **RPN4**, a transcription factor and master regulator of proteasome, RPN4Δ strains grown in YPGal and treated with 30 mM LiCl for 1 h (n = 3–4 biological replicates). One-way ANOVA with Dunnett’s multiple comparison test was performed, and we did not observe any statistically significant difference between the groups.

A hypothesis to explain the decreased tolerance to lithium and galactose observed in the **ubx4Δ** strain is that, under this condition, cells are more dependent on respiration, and because the **ubx4Δ** strain presents a decreased mitochondrial oxygen consumption rate, it cannot grow properly. This is in line with previous data from our group showing that lithium–galactose–treated control cells have a metabolic shift from fermentation to respiration (11). Accordingly, if we simulate the **ubx4Δ** defects in both galactose and mitochondrial metabolism by growing the **gal1Δ** strain in the presence of antimycin A, an inhibitor of mitochondrial complex III, the cells become unable to grow on galactose (Fig. 4B).

A strategy to reduce lithium–galactose toxicity is to prevent galactose-1-phosphate accumulation (3, 4, 34). We assumed that because the deletion of **UBX4** decreases intracellular galactose-1-phosphate content, the **ubx4Δ** would be more tolerant to the treatment of lithium and galactose. Surprisingly, we observed that **UBX4** deletion results in a decreased cellular tolerance to lithium in galactose-containing medium but not in glucose-containing medium (Fig. 3A). A decrease of ERAD or proteasome cellular function does not explain this increased sensitivity because neither the deletion of **RPN4** nor the deletion of **UBC7** modified the cellular sensitivity to lithium and galactose (Fig. 3B). We also tested mutations in other components of these pathways but could not observe significant differences in cell growth among those strains (Fig. S2).

Our data suggested that the deletion of **UBX4** might be acting on the lithium–galactose tolerance via other mechanism rather than regulating galactose metabolism. Previous work suggested that the deletion of the **UBX4** gene increases the frequency of petite colonies, which in general is related to deficiencies in mitochondrial metabolism (35). Hence, we monitored the respiration capacity of this strain, and we observed a greater than 10-fold decrease in oxygen consumption rate in the **ubx4Δ** cells compared with the cells of a control strain when grown in galactose (Fig. 4A). The impaired galactose metabolism observed in **ubx4Δ** does not seem to be solely responsible for the decreased mitochondrial respiration because the **gal1Δ** strain, which cannot metabolize galactose because of the lack of galactokinase, presents only a slight decrease in mitochondrial oxygen consumption under the same conditions. This result is expected because these strains are growing in a rich medium containing other carbon sources, such as amino acids, which can sustain mitochondrial respiration when galactose metabolism is impaired. We also observed that the deletion of **UBX4** reduced oxygen consumption in the absence of galactose metabolism, for example, when cells were grown on YPGly (medium containing glycerol, a nonfermentable carbon source) (Fig. S3A).

The deletion of neither **UBC7** nor **RPN4** affected oxygen consumption rates (Fig. 4A and Fig. S3A), suggesting that an impairment of ERAD or proteasome function does not contribute for this **ubx4Δ** phenotype. The fact that mitochondrial preparations from **ubx4Δ** cells present decreased oxygen consumption capacity when compared with mitochondrial preparations from a control yeast strain (Fig. S3, B and C) further supports the hypothesis that the effect of **UBX4** deletion on oxygen consumption *in vivo* is not only due to its impact on galactose metabolism.

A hypothesis to explain the decreased tolerance to lithium and galactose observed in the **ubx4Δ** strain is that, under this condition, cells are more dependent on respiration, and because the **ubx4Δ** strain presents a decreased mitochondrial oxygen consumption rate, it cannot grow properly. This is in line with previous data from our group showing that lithium–galactose–treated control cells have a metabolic shift from fermentation to respiration (11). Accordingly, if we simulate the **ubx4Δ** defects in both galactose and mitochondrial metabolism by growing the **gal1Δ** strain in the presence of antimycin A, an inhibitor of mitochondrial complex III, the cells become unable to grow on galactose (Fig. 4B).

We reasoned that mitochondrial function could be upstream of galactose metabolism and UPR activation in lithium-treated yeast cells. Accordingly, previous studies showed that **GAL1** gene expression is down-regulated in strains with mutations in components of the mitochondrial electron transport chain or in yeast strains with reduced mitochondrial membrane potential (36, 37). On the other hand, another study observed that yeast cells depleted of mitochondrial DNA (rho0) present an increase in Gal4-dependent transcription (38). Nevertheless, it

*Ubx4p regulates yeast mitochondrial respiration*
remains to be tested whether mitochondrial dysfunction promotes alterations in galactose metabolite levels. To test these hypotheses under our growth conditions, we first inhibited yeast mitochondrial function by deleting COQ3 or ATP7 genes, which impairs mitochondrial respiratory chain function (39–41) (Fig. 5A). These mutants recapitulated all ubx4Δ phenotypes, including decreased cell growth on lithium and galactose (Fig. 5A), the decrease in galactose-1-phosphate levels (*p < 0.0001 two-way ANOVA 30 mM of LiCl; control strain versus atp7Δ/H9004 or coq3Δ/H9004) (Table 1), and the defect in HAC1 mRNA splicing induced by lithium and galactose treatment (Fig. 5B).

It was previously observed that the deletion of the yeast AMPK homolog SNF1 increases the oxygen consumption rate when yeast cells are grown in glucose medium (42). We observed a similar increase when snf1Δ strains were grown in the presence of galactose (Fig. 6A). We then deleted the SNF1 gene in the ubx4Δ strain to test whether this deletion could recover ubx4Δ mitochondrial function. Surprisingly, SNF1 deletion totally recovered ubx4Δ oxygen consumption capacity (Fig. 6A). Accordingly, the deletion of SNF1 was capable of recovering the adaption capacity to lithium and galactose treatment and the UPR activation of the ubx4Δ strain (Fig. 6, B and C). When we measured galactose-1-phosphate levels in these mutants, we noted that the deletion of SNF1 partially recovered galactose-1-phosphate levels in the ubx4Δ strain growing in YPGal (Table 1). Despite the fact that snf1Δ cells treated with lithium and galactose exhibited an ~40% reduction in galactose-1-phosphate levels when compared with the control strain (Table 1) (*p < 0.0001 two-way ANOVA 30 mM of LiCl; control strain versus snf1Δ), the deletion of SNF1 partially restored the levels of galactose-1-phosphate in the ubx4Δ strain (Table 1) (*p = 0.0677 two-way ANOVA 30 mM of LiCl; ubx4Δ versus ubx4Δsnf1Δ). Galactose-1-phosphate is believed to be a toxic metabolite in the cell when accumulated, and although the ubx4Δsnf1Δ strain has higher levels of galactose-1-phosphate than the ubx4Δ mutant, the former grows better when treated with lithium and galactose, probably because of the increase in the oxygen consumption rate mediated by the deletion of SNF1.

**Discussion**

In this work, we showed that **UBX4** is necessary for proper UPR activation in cells treated with lithium in the presence of galactose. We presented evidences that **UBX4** does not regulate Ire1p activity directly. Instead, it diminishes ER stress by decreasing the intracellular content of galactose-1-phosphate (and possibly other Leloir pathway metabolites), accumulation of which is necessary for UPR activation in these conditions (3). Curiously, we did not observe any changes in UPR activation in
strains that are defective in ERAD or proteasome activity, suggesting that the effect of UBX4 deletion does not relate to these previously described Ubx4p functions. Importantly, we found that UBX4 deletion has an impact on mitochondrial oxygen consumption rates, which in turn affects galactose metabolism and consequently UPR activation in lithium–galactose–treated cells (Fig. 6D).

The human homolog of Ubx4p, TUG/ASPSCR1, was initially described as a GLUT4 tether, which interacts with this transporter via its conserved UBX domain, thus regulating GLUT4 desorption from insulin stimulation (27). Curiously, our data show that ubx4Δ has reduced levels of intracellular galactose, even when compared with that of atp7Δ or coq3Δ mutants. That could be explained if yeast Ubx4p could directly regulate hexose carrier activity. It will be interesting to test this possibility in the future. This is in agreement with data showing that the galactose transporter GAL2 mRNA level was not reduced on ubx4Δ strain (Fig. 1C), indicating that GAL2 could be regulated at the post-transcriptional level.

To test whether UBX4 homologs have conserved this mitochondria-related function, we compared the mitochondrial oxygen consumption rates of the Caenorhabditis elegans strain asps-1(ok915), carrying a mutation in the UBX4 homolog gene, with that of a control strain N2. Although we observed that asps-1(ok915) mutant has slow larval development (data not shown), a phenotype observed in other C. elegans mutants with mild mitochondrial dysfunction (43–45), we could not observe alterations in mitochondrial oxygen consumption in this mutant (Fig. S4). Although Ubx4p may not have a conserved role in mitochondrial function in C. elegans, we also speculate that asps-1 can have a conditional or tissue-specific function that is not reflected by the assay performed with whole adult worms under the specific conditions used. Supporting this notion, it was recently observed that muscle-specific TUG/ASPSCR1 deletion decreases oxygen consumption and influences mitochondrial morphology only when mice are subjected to a high-fat diet (46). Although other experiments need to be performed to fully address this issue, these results suggest that Ubx4p homologs can also impact mitochondrial function in metazoans.

So, how does the deletion of UBX4 causes dysfunction in mitochondrial metabolism? We measured the mitochondrial DNA content per cell as an indicator of the total mitochondrial content but could not observe any difference between ubx4Δ and control strains (Fig. S5A). However, we did observe a decreased respiratory capacity of mitochondria preparations from ubx4Δ cells when compared with preparations from control cells (Fig. S3, B and C), indicating that the mitochondria itself is functionally affected by the deletion of UBX4. We also reasoned that the ubx4Δ strain could manifest redox alterations that might explain the decrease in cell growth. We tested whether the supplementation with the antioxidant N-acetyl-cysteine would recover ubx4Δ growth on lithium and galactose, but no significant difference was observed (Fig. S5B). Recently, another protein that contains the UBX domain involved in ERAD pathway, Ubx2p, was shown to be necessary for solving defects in mitochondrial protein translocation via regulation of Cdc48p activity associated with the TOM complex (47). We tested whether the deletion of UBX2 would mimic the phenotype observed in ubx4Δ of reduced growth on lithium and

Table 1

| Strain        | Treatment                  | Galactose (nmol/O.D.) | Galactose-1-phosphate (nmol/O.D.) |
|---------------|----------------------------|-----------------------|-----------------------------------|
| Control       | YPGal                      | 1.07 ± 0.87           | 1.31 ± 0.91                       |
| ubx4Δ         | YPGal                      | 0.16 ± 0.17           | 0.09 ± 0.09                       |
| snf1Δ         | YPGal                      | 1.19 ± 0.83           | 1.40 ± 0.92                       |
| ubx4Δsnf1Δ    | YPGal                      | 0.52 ± 0.30           | 0.89 ± 0.67                       |
| coq3Δ         | YPGal                      | 0.32 ± 0.09           | 0.046 ± 0.08                      |
| atp7Δ         | YPGal                      | 1.16 ± 0.92           | 0.18 ± 0.18                       |
| Control       | YPGal + 30 mM LiCl (1 h)   | 11.99 ± 4.10          | 9.45 ± 1.61                       |
| ubx4Δ         | YPGal + 30 mM LiCl (1 h)   | 2.11 ± 1.49           | 2.11 ± 1.02                       |
| snf1Δ         | YPGal + 30 mM LiCl (1 h)   | 6.26 ± 1.98           | 6.50 ± 1.35                       |
| ubx4Δsnf1Δ    | YPGal + 30 mM LiCl (1 h)   | 2.94 ± 1.17           | 3.94 ± 1.39                       |
| coq3Δ         | YPGal + 30 mM LiCl (1 h)   | 4.88 ± 1.42           | 2.46 ± 0.20                       |
| atp7Δ         | YPGal + 30 mM LiCl (1 h)   | 6.88 ± 3.82           | 2.5 ± 0.65                        |
galactose, but we did not observe any significant differences on ubx2/H9004 strain growth under this condition (Fig. S2). This result suggests that Ubx2p and Ubx4p have distinct roles to sustain mitochondrial function, at least when cells are grown on galactose. Supporting this hypothesis, it was already shown that Cdc48p has distinct roles in regulating mitochondrial morphology, proteostasis, and yeast capacity to grow in medium containing respiratory carbon source (48–51). Despite our results suggesting that proteasome function may not be involved with the mitochondrial phenotypes of the ubx4/H9004 strain, it has been determined that the ubiquitin–proteasome system is involved in the control of mitochondrial function (52). We are currently trying to understand mechanistically the role of Ubx4p in the function of mitochondria, including a possible cooperation with Cdc48p.

It has been previously shown that when yeast cells are grown in the presence of galactose, inhibition of phosphoglucomutase activity by either PGM2 gene deletion or lithium treatment results in an increase in cellular calcium uptake and UPR activation and negatively impacts cell growth (10, 53, 54). It was proposed that the increased cellular calcium accumulation is induced by an increase in the glucose-1-phosphate/glucose-6-phosphate ratio because the deletion of the PFK2 gene (which encodes for phosphofructokinase) decreases the glucose-1-phosphate/glucose-6-phosphate ratio and concomitantly suppresses intracellular calcium accumulation (10, 55). We found that PFK2 gene deletion did not affect UPR activation by lithium and galactose treatment (Fig. S6A), although it did confer some growth tolerance (Fig. S6B) as previously reported (10). These results suggest that the UPR activation observed under our experimental conditions is not influenced by the glucose-1-phosphate/glucose-6-phosphate ratio.

The deletion of the yeast AMPK/SNF1 gene increases oxygen consumption in control and ubx4/H9004 cells, allowing a normal galactose metabolism and UPR activation with the treatment of lithium. Although in mammals the role of AMPK to sustain oxidative metabolism is well-characterized (56), in yeast the deletion of SNF1 seems to increase mitochondrial respiration by enhancing amino acid uptake and utilization (42). The deletion of SNF1 was already shown to regulate UPR activation in cells treated with tunicamycin (57). The relationship between ER stress and mitochondria was further explored by a recent study showing that mitochondrial function is necessary for cellular adaptation to DTT or tunicamycin (58). Thus, different ER stress conditions may share pathways to mediate the communication between mitochondria and the ER to allow the cell to adapt to stress.

In this work, we show interorganelle communication between mitochondria and ER through the regulation of galactose metabolism. Mitochondria during stressful conditions, such as
impairment of proteostasis or energy deprivation, can send signals to the nucleus in a form of retrograde signaling to re-establish homeostasis (59). In yeast, one mechanism to mediate this communication is through the RTG pathway (60). Nevertheless, we did not observe a correlation between the decreased oxygen consumption rates and increased expression of the CIT2 gene, a target of the RTG pathway, in the \( \text{ubx4}\Delta \) strain (data not shown). Still, it will be interesting to test whether this signaling between mitochondria and galactose metabolism is conserved in other biological systems. In mammals, galactose metabolism is regulated by UPR after feeding (61). Thus, it is tempting to conceive that our results are a description of a C/EBP \( \beta \)-like receptor that was modified during evolution to adapt to galactose toxicity in the context of postprandial metabolic changes. Our findings provide a link between mitochondrial homeostasis and UPR activation regulated by Ubx4p and contribute to our understanding of toxicity mediated by lithium and by galactose metabolism disturbances.

## Experimental procedures

### Yeast strains and growth conditions

Unless otherwise stated, all Saccharomyces cerevisiae strains used in this work are derived from the MATa deletion library (Open Biosystems) and have the same background of BY4741 (MATa, his3Δ1, leu2Δ0, met15Δ0, ura3Δ0). The strain lys2Δ was used as control strain in our assays, labeled as a control in the figures, because most strains derived from the deletion library are slightly more resistant to lithium and galactose than the parental BY4741 strain (3). Yeast cells were grown by shaking at 30 °C in YM medium (1% yeast extract, 2% Bacto peptone) containing 2% glucose (YPD), 2% galactose (YPGal), or 2% glycerol (YPGly). For plates, 2% of agar was included in the medium. Antimycin A (ethanol), N-acetylcycteine (water), and lithium chloride (water) were obtained from Sigma–Aldrich. The double mutant \( \text{ubx4}\Delta \text{snf1}\Delta \) was generated by crossing a haploid MATa \( \text{ubx4}\Delta \) strain with a haploid MATa \( \text{snf1}\Delta \) strain previously generated by our group (62). Strains were genotyped using the following primers: SNF1A (5'-TAAAGATATGGC-ACATCAACAGGTA-3'), SNF1D (5'-TGTAGTAGTTTG-ATTTTTGTCGCA-3'), UBX4A (5'-TAAAACGCTAGATGCATTCTGTC-3'), UBX4D (5'-GAATACAAATATCC-CATTTTGATCAGG-3'), kanB (5'-CTGCAGAGGAGGCG-GTAAT-3'), and kanC3 (5'-CCTCGACATCATCTGGCATAGGGA-3').

### HAC1 transcript splicing analysis

Total RNA was extracted as previously described (3) from cells grown to the exponential phase (\( \sim 0.3 \text{ A}_{600 \text{ nm}} \)) under the conditions described in each experiment. A total of 1 µg of total RNA was used to prepare the first-strand cDNA using a high-capacity cDNA reverse-transcription kit following the manufacturer’s protocol (Applied Biosystems, Foster City, CA). The cDNA was used as a template for the amplification of HAC1 cDNA by PCR. The PCR conditions were 94 °C for 1 min followed by 35 cycles at 94 °C for 30 s, 62 °C for 30 s, 72 °C for 90 s, and a final step of 72 °C for 10 min. The primers used in these reactions were HAC1F (5'-GACCACGAGACGCAGTTG-3') and HAC1R (5'-TCAAATGAAATCAACCTGACTG-3').

### Quantitative RT-PCR

Total RNA extraction and first-strand cDNA synthesis were performed as described under “HAC1 transcript splicing analysis.” Quantitative PCR was performed with the StepOnePlus real-time PCR system (Applied Biosystems) with the PCR protocol as one cycle for 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C and 45 s at 60 °C, using Power SYBR-Green PCR master mix (Applied Biosystems). The relative expression levels were calculated using the comparative Ct method (63) using TFC1 as a reference gene (64). The sequences of the primers used in this section are TFC1F (5'-TGGATGAGCGGTAG-GCAGAT-3'), TFC1R (5'-GCTGCGATTTTCAATTTTCC-3'), GAL1F (5'-TTGCGACACCCCTTGTGTA-3'), GAL1R (5'-CGTGCGATCTTTCCCTTTT-3'), GAL2F (5'-GTCAGTGGCCTGATGATT-3') and GAL2R (5'-TCCCAAATTTTCCAGACGTC-3'). For the experiments measuring mitochondrial DNA content, we extracted the DNA as previously described (65, 66). Briefly, strains had their DNA extracted by basic phenol (pH 8.0) and chloroform (1:1) and precipitated with ethanol containing 0.3 M of sodium acetate. The primers used were COX3F (5'-TTGAAAGCTGTC-AACCTC-3'), COX3R (5'-CCTGCGATTAAAGCATGATG-3'), TAF10F (5'-TCCCCAGGTATTGCGAA-3'), and TAF10R (5'-TTGCGGTGAAGCGATATGGA-3').

### Plate growth assay

The cells were grown overnight, and by using a replica plater for 96-well plates (Sigma R2508), serial dilutions of the cultures (prepared in sterile-distilled water to \( \text{A}_{600 \text{ nm}} \) values of 0.3, 0.03, and 0.003) were transferred to plates containing the indicated medium in the figure legends. The plates were incubated at 30 °C for 3 days and then photographed. The images were processed using the Adobe Photoshop software.

### Measurement of intracellular galactose and galactose-1-phosphate levels

Yeast cultures were inoculated in YPGal and maintained at 30 °C with agitation (200 rpm) until an \( \text{A}_{600 \text{ nm}} \) of \( \sim 0.2 \) was reached. At this point, lithium chloride (30 mM) was added to the media, and after 1 h, the cells were collected and processed as previously described (9).

### Respiration rate in vivo

The cells were grown at YPGal or YPGly until an \( \text{A}_{600 \text{ nm}} \) of 0.5 was reached and then collected by centrifugation. The cells were suspended at their respective medium to achieve a concentration of 0.1 \( \text{A}_{600 \text{ nm}} \), and their oxygen consumption rates were measured using the O2k oxygraph of high resolution (Oroboros) at 30 °C. After the total oxygen consumption rate was measured, antimycin A was added (final concentration used was 1 µM) to estimate the mitochondrial (antimycin A–sensitive) oxygen consumption rate.

### Respiration rate in vitro

Yeast cells were grown in YPGly medium up to mid-log phase and \( \sim 100 \text{ A}_{600 \text{ nm}} \) of cells were harvested by centrifugation.
Ubx4p regulates yeast mitochondrial respiration

(3,000 × g, 5 min) for mitochondria isolation as described previously (67), using 100 mg/ml of the Lallzyme MMX enzyme for cell wall digestion (Lallemand/GER) instead of Zymolyase. After isolation, mitochondria protein content was determined by the Lowry method, and the amount relative to 200 μg of proteins of the mitochondria preparation was added to the Oroboros O2k chamber containing respiration medium (0.6 M mannitol, 10 mM K2HPO4, 2 mM MgCl2, 20 mM Hepes, pH 6.8). Glycerol-3-phosphate (30 mM), pyruvate (10 mM), malate (5 mM), and succinate (20 mM) salts were added to load the electron transport chain of isolated mitochondria, and the oxygen consumption rate was determined (nonphosphorylation state of respiration). Then the oxygen consumption rate was measured in the presence of an excess (1 mM) of ADP (phosphorylation state of respiration). The mitochondria preparation of isolated mitochondria, and the oxygen consumption rate was determined (nonphosphorylation state of respiration), and the respiratory control ratio was calculated between the two states of respiration. After the total oxygen consumption rates were measured in the two states of respiration, antimycin A was added (1 micromolar) to estimate the mitochondrial (antimycin A-sensitive) oxygen consumption rate. Finally, cytochrome c (0.5 μM) was added to inform the integrity of the membranes of the mitochondria preparation.

C. elegans experiments

Worms were grown at 20 °C as previously described (68, 69). We used the WT N2 and asp-1(ok915) V/RB994 strains. For the oxygraphy experiments, the worms were grown in Escherichia coli OP-50 as the food source until day 0 of adulthood at a density of ~12,000 worms/plate (90 × 15 mm). Adult worms at day 0 of adulthood were washed out from plates with MilliQ water and transferred to microtubes at a final density of 4,000–7,000 worms/biological replicate. The worms were washed two additional times with MilliQ water to remove bacteria. The water was removed, and M9 buffer was added. Oxygen consumption rate was measured at O2K oxygraph of high resolution (Oroboros) at 20 °C in M9 buffer. After oxygen consumption measurement, sodium azide was added (final concentration used was 10 mM) to estimate the organism mitochondrial oxygen consumption rate. At the end of the assay, the worms were transferred to a safe-lock tube; supernatant was removed after decantation of the worms, and the tubes were quickly frozen in liquid nitrogen. For protein extraction, 500 μl of radioimmune precipitation assay buffer was added to frozen samples and worms lysed using Bullet Blender Tissue Lyzer (two cycles of 3 min at speed 7). The samples were kept on ice for 30 min, with gentle mixing every 10 min, and centrifuged at 14,000 × g for 30 min at 4 °C. The supernatant containing proteins was diluted 10× and used for protein quantification by BCA protein assay kit (Pierce). Oxygen consumption rates were normalized by protein levels.

Statistical analysis

All data are presented as means ± S.D. or ± S.E. We used GraphPad Prism version 6.00 for Windows (GraphPad Software) for all analysis in this work. The specific tests and post hoc tests are indicated in the figures legends.

References

1. Phiel, C. J., and Klein, P. S. (2001) Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 41, 789–813 CrossRef Medline
2. Masuda, C. A., Xavier, M. A., Mattos, K. A., Galina, A., and Montero-Lomelí, M. (2001) Phosphoglucomutase is an in vivo lithium target in yeast. J. Biol. Chem. 276, 37794–37801 Medline
3. De-Souza, E. A., Pimentel, F. S., Machado, C. M., Martins, L. S., da-Silva, W. S., Montero-Lomelí, M., and Masuda, C. A. (2014) The unfolded protein response has a protective role in yeast models of classic galactosemia. Dis. Model. Mech. 7, 55–61 CrossRef Medline
4. Masuda, C. A., Prevìato, J. O., Miranda, M. N., Assis, L. J., Penha, L. H., Mendoça-Prevìato, L., and Montero-Lomelí, M. (2008) Overexpression of the aldose reductase GRE3 suppresses lithium-induced galactose toxicity in Saccharomyces cerevisiae. FEBS. Yeast Res. 8, 1245–1253 CrossRef Medline
5. Nagy, T., Frank, D., Kátaí, E., Yahiro, R. K., Poós, V., Montsók, G., Zrínyi, Z., Kovács, G. L., and Miseta, A. (2013) Lithium induces ER stress and N-glycan modification in galactose-grown Jurkat cells. PLoS One 8, e70410 CrossRef Medline
6. Berry, G. T. (2017) in Classic Galactosemia and Clinical Variant Galactosemia (Adam, M., Arding, H., Pagon, R., Wallace, S., Bean, L., Stephens, K., Anemiya, A., eds) University of Washington, Seattle
7. Fridovich-Keil, I. L. (2006) Galactosemia: the good, the bad, and the unknown. J. Cell. Physiol. 209, 701–705 CrossRef Medline
8. Botstein, D., Chervitz, S. A., and Cherry, J. M. (1997) Yeast as a model organism. Science 277, 1259–1260 CrossRef Medline
9. Machado, C. M., De-Souza, E. A., De-Queirõz, A. L. F. V., Pimentel, F. S. A., Silva, G. F. S., Gomes, F. M., Montero-Lomelí, M., and Masuda, C. A. (2017) The galactose-induced decrease in phosphate levels leads to toxicity in yeast models of galactosemia. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 1403–1409 CrossRef Medline
10. Csutora, P., Strassz, A., Boldizsár, F., Németh, P., Sipos, K., Aiello, D. P., Bedwell, D. M., and Miseta, A. (2005) Inhibition of phosphoglucomutase activity by lithium alters cellular calcium homeostasis and signaling in Saccharomyces cerevisiae. Am. J. Physiol. Cell Physiol. 289, C58–C67 CrossRef Medline
11. Bro, C., Regenberg, B., Lagniel, G., Labarre, J., Montero-Lomelí, M., and Nielsen, J. (2003) Transcriptional, proteomic, and metabolic responses to lithium in galactose-grown yeast cells. J. Biol. Chem. 278, 32141–32149 CrossRef Medline
12. Slepk, T. I., Tang, M., Slepk, V. Z., and Lai, K. (2007) Involvement of endoplasmic reticulum stress in a novel classic galactosemia model. Mol. Genet. Metab. 92, 78–87 CrossRef Medline
Balakrishnan, B., Chen, W., Tang, M., Huang, X., Cakici, D. D., Siddiqi, A., Berry, G., and Lai, K. (2016) Galactose-1-phosphate uridyltransferase (GALT) gene: A novel positive regulator of the PI3K/Akt signaling pathway in mouse fibroblasts. *Biochem. Biophys. Res. Commun.* 470, 205–212 CrossRef Medline

Cox, J. S., and Walter, P. (1996) A novel mechanism for regulating activity of a transcription factor that controls the unfolded protein response. *Cell* 87, 391–404 CrossRef Medline

Ron, D., and Walter, P. (2007) Signal integration in the endoplasmic reticulum unfolded protein response. *Nat. Rev. Mol. Cell Biol.* 8, 519–529 CrossRef Medline

Travers, K. J., Patil, C. K., Wodicka, L., Lockhart, D. J., Weissman, J. S., and Walter, P. (2000) Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. *Cell* 101, 249–258 CrossRef Medline

Henis-Korenblit, S., Zhang, P., Hansen, M., McCormick, M., Lee, S.-J., Cary, M., and Kenyon, C. (2010) Insulin/IGF-1 signaling mutants program ER stress response regulators to promote longevity. *Proc. Natl. Acad. Sci. U.S.A.* 107, 9730–9735 CrossRef Medline

Hartmann-Petersen, R., and Gordon, C. (2004) Integral UBL domain proteins of the endoplasmic reticulum—associates degradation pathways of budding yeast. *Cold Spring Harb. Perspect. Biol.* 4, pii: a013193 CrossRef

Alberts, S. M., Sonntag, C., Schäfer, A., and Wolf, D. H. (2009) Ubx4 modulates cdc48 activity and influences degradation of misfolded proteins of the endoplasmic reticulum. *J. Biol. Chem.* 284, 16082–16089 CrossRef Medline

Chien, C.-Y., and Chen, R.-H. (2013) Cdc48 chaperone and adaptor Ubx4 distribute the proteasome in the nucleus for anaphase proteolysis. *J. Biol. Chem.* 288, 37180–37191 CrossRef Medline

Decottignies, A., Evain, A., and Ghislain, M. (2004) Binding of Cdc48p to a ubiquitin-related UBX domain from novel yeast proteins involved in intracellular proteolysis and sporation. *Yeast* 21, 127–139 CrossRef Medline

Hartmann-Petersen, R., and Gordon, C. (2004) Integral UBL domain proteins: a family of proteasome interacting proteins. *Semin. Cell. Dev. Biol.* 15, 247–259 CrossRef Medline

Madsen, L., Molbaek, K., Larsen, I. B., Nielsen, S. V., Poulsen, E. G., Walmod, P. S., Hofmann, K., Seeger, M., Chien, C.-Y., Chen, R.-H., Kriegenburg, F., and Hartmann-Petersen, R. (2014) Human ASPL/TUG interacts with p97 and complements the proteasome mislocalization of a misfolded luminal protein by the cytosolic ubiquitin–proteasome pathway. *Science* 273, 1725–1728 CrossRef Medline

Mannhaupt, G., Schnall, R., Karpov, V., Vetter, I., and Feldmann, H. (1999) Rpn4p acts as a transcription factor by binding to PACE, a nonamer box found upstream of 26S proteasomal and other genes in yeast. *FEBS Lett.* 450, 27–34 CrossRef Medline

Xie, Y., and Varshavsky, A. (2001) RPN4 is a ligand, substrate, and transcriptional regulator of the 26S proteasome: a negative feedback circuit. *Proc. Natl. Acad. Sci. U.S.A.* 98, 3056–3061 CrossRef Medline

Jelinsky, S. A., Estep, P., Church, G. M., and Samson, L. D. (2000) Regulatory networks revealed by transcriptional profiling of damaged *Saccharomyces cerevisiae* cells: Rpn4 links basic excision repair with proteasomes. *Mol. Cell. Biol.* 20, 8157–8167 CrossRef Medline

Lai, K., Boxer, M. B., and Marabotti, A. (2014) GALK inhibitors for classic galactosia. *Future Med. Chem.* 6, 1003–1015 CrossRef Medline

Hess, D. C., Myers, C. L., Huttenhower, C., Hibs, M. A., Hayes, A. P., Paw, J., Clore, J. J., Mendoza, R. M., Luis, B. S., Nislow, C., Giaever, G., Costanzo, M., Troyanskaya, O. G., and Caudy, A. A. (2009) Computationaly driven, quantitative experiments discover genes required for mitochondrial biogenesis. *PLoS Genet.* 5, e1000407 CrossRef Medline

Li, Y., Chen, G., and Liu, W. (2010) Multiple metabolic signals influence GAL gene activation by modulating the interaction of Gal80p with the transcriptional activator Gal4p. *Mol. Microbiol.* 78, 414–428 CrossRef Medline

Ferreira Júnior, J. R., Ramos, A. S., Chamberto, F. S., Stambuk, B. U., Muschellack, L. K., Schumacher, R., and El-Dorry, H. (2006) Functional expression of the maize mitochondrial URI13 down-regulates galactose-induced GAL1 gene expression in *Saccharomyces cerevisiae*. *Biochem. Biophys. Res. Commun.* 339, 30–36 CrossRef Medline

Rea, S. L., Ventura, N., and Johnson, T. E. (2007) Relationship between mitochondrial unfolded protein response and stress factor ATFS-1 promotes longevity in a long-lived mitochondrial mutant through activation of stress response pathways. *FEBS Lett.* 523, 207–213 CrossRef Medline

Clarke, C. F., Williams, W., and Teruya, J. H. (1991) Ubiquinone biosynthesis in *Saccharomyces cerevisiae*: isolation and sequence of COQ3, the 3,4-dihydroxy-5-hexaprenylbenzoate methyltransferase gene. *J. Biol. Chem.* 266, 16636–16644 Medline

Mårtensson, C. U., Priesnitz, C., Song, J., Ellenrieder, L., Doan, K. N., Boos, G., M., Troyanskaya, O. G., and Caudy, A. A. (2009) Computationaly driven, quantitative experiments discover genes required for mitochondrial biogenesis. *PLoS Genet.* 5, e1000407 CrossRef Medline

Graef, M., and Nunnari, J. (2011) Mitochondria regulate autophagy by conserved signalling pathways. *EMBO J.* 30, 2101–2114 CrossRef Medline

Nicastro, R., Tripodi, F., Guzzi, C., Reghelli, V., Khoornum, S., Capucosi, C., Compagn, C., Airolidi, C., Nielsen, J., Alberghina, L., and Coccetti, P. (2015) Enhanced amino acid utilization sustains growth of cells lacking Snf1/AMPK. *Biochim. Biophys. Acta* 1853, 1615–1625 CrossRef Medline

Hartmann-Petersen, R., and Gordon, C. (2004) Integral UBL domain proteins: a family of proteasome interacting proteins. *Semin. Cell. Dev. Biol.* 15, 247–259 CrossRef Medline

Madsen, L., Molbaek, K., Larsen, I. B., Nielsen, S. V., Poulsen, E. G., Walmod, P. S., Hofmann, K., Seeger, M., Chien, C.-Y., Chen, R.-H., Kriegenburg, F., and Hartmann-Petersen, R. (2014) Human ASPL/TUG interacts with p97 and complements the proteasome mislocalization of a yeast ubx4 mutant, but not the ER-associated degradation defect. *BMC Cell Biol.* 15, 31 CrossRef Medline

Bogan, J. S., Hendon, N., McKee, A. E., Tsao, T.-S., and Lodish, H. F. (2003) Functional cloning of TUG as a regulator of GLUT4 glucose transporter trafficking. *Nature* 425, 727–733 CrossRef Medline

Bogan, J. S., Rubin, B. R., Yu, C., Löffler, M. G., Orme, C. M., Belman, J. P., McNally, L. L., Hao, M., and Cresswell, J. A. (2012) Endoproteolytic cleavage of TUG protein regulates GLUT4 glucose transporter translocation. *J. Biol. Chem.* 287, 23932–23947 CrossRef Medline

Yu, C., Cresswell, J., Löffler, M. G., and Bogan, J. S. (2007) The glucose transporter 4-regulating protein TUG is essential for highly insulin-responsive glucose uptake in 3T3-L1 adipocytes. *J. Biol. Chem.* 282, 7710–7722 CrossRef Medline

Miller, M. M., Finger, A., Schweiger, M., and Wolf, D. H. (1996) ER degradation of a misfolded luminal protein by the cytosolic ubiquitin–proteasome pathway. *Science* 273, 1725–1728 CrossRef Medline

Mannhaupt, G., Schnall, R., Karpov, V., Vetter, I., and Feldmann, H. (1999) Rpn4p acts as a transcription factor by binding to PACE, a nonamer box found upstream of 26S proteasomal and other genes in yeast. *FEBS Lett.* 450, 27–34 CrossRef Medline

Xie, Y., and Varshavsky, A. (2001) RPN4 is a ligand, substrate, and transcriptional regulator of the 26S proteasome: a negative feedback circuit. *Proc. Natl. Acad. Sci. U.S.A.* 98, 3056–3061 CrossRef Medline
**Ubx4p regulates yeast mitochondrial respiration**

Rutter, J. (2018) Vma1p is a release factor for the ribosome-associated quality control complex. *Nat. Commun.* 9, 2197 CrossRef Medline

50. Izawa, T., Park, S.-H., Zhao, L., Hartl, F. U., and Neupert, W. (2017) Cytosolic protein Vma1 links ribosome quality control to mitochondrial and cellular homeostasis. *Cell* 171, 890–903 e18 CrossRef Medline

51. Braun, R. J., Zischka, H., Arvan, P., and Chang, A. (2019) Increased mitochondrial respiration promotes survival from endoplasmic reticulum stress. *J. Biol. Chem.* 284, 25757–25767 CrossRef Medline

52. Bragoszewski, P., Turek, M., and Chacinska, A. (2017) Control of mitochondrial biogenesis and function by the ubiquitin: proteasome system. *Open Biol.* 7, 170007 CrossRef Medline

53. Fu, L., Miseta, A., Hunton, D., Marchase, R. B., and Bedwell, D. M. (2000) Loss of the major isoform of phosphoglucomutase results in altered calcium homeostasis in *Saccharomyces cerevisiae*. *J. Biol. Chem.* 275, 5431–5440 CrossRef Medline

54. Aiello, D. P., Fu, L., Miseta, A., Sipos, K., and Bedwell, D. M. (2004) The Ca^{2+} homeostasis defects in a pgm2Delta strain of *Saccharomyces cerevisiae* are caused by excessive vacuolar Ca^{2+} uptake mediated by the Ca^{2+}-ATPase Pmc1p. *J. Biol. Chem.* 279, 38495–38502 CrossRef Medline

55. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25, 402–408 CrossRef Medline

56. Butow, R. A., and Avadhani, N. G. (2004) Mitochondrial signaling: the retrograde response. *Mol. Cell.* 14, 1–15 CrossRef Medline

57. Sun, M., Chen, Z., Ouyang, Y., Zhao, X., Zhao, Z., Han, S., Pei, Z., Zhang, H., Zeng, W., Wang, B., Chen, Z., Wu, X., and Liu, H. (2015) The Xbp1s/GalE axis links ER stress to postprandial hepatic metabolism. *J. Clin. Invest.* 125, 455–468 CrossRef Medline

58. Haynes, C. M., Fiorese, C. J., and Lin, Y.-F. (2013) Evaluating and responding to mitochondrial dysfunction: the mitochondrial unfolded-protein response and beyond. *Trends Cell Biol.* 23, 311–318 CrossRef Medline

59. Haynes, C. M., Fiorese, C. J., and Lin, Y.-F. (2013) Cytosolic protein Vma1 links ribosome quality control to mitochondrial and cellular homeostasis. *Cell* 171, 890–903 e18 CrossRef Medline

60. Butow, R. A., and Avadhani, N. G. (2004) Mitochondrial signaling: the retrograde response. *Mol. Cell.* 14, 1–15 CrossRef Medline

61. Deng, Y., Wang, Z. Y., Tao, C., Gao, N., Holland, W. L., Ferdous, A., Repa, J. J., Liang, G., Ye, J., Lehrman, M. A., Hill, J. A., Horton, J. D., and Scherer, P. E. (2013) The Xbp1s/GalE axis links ER stress to postprandial hepatic metabolism. *J. Clin. Invest.* 123, 455–468 CrossRef Medline

62. Bozaquel-Morais, B. L., Madeira, J. B., Venâncio, T. M., Pacheco-Rosa, T., Masuda, C. A., and Montero-Lomeli, M. (2017) A chemogenomic screen reveals novel Snf1p/AMPK independent regulators of acetyl-CoA carboxylase. *PLoS One* 12, e0169682 CrossRef Medline

63. Aiello, D. P., Fu, L., Miseta, A., and Bedwell, D. M. (2002) Intracellular calcium homeostasis defects in a pgm2Delta strain of *Saccharomyces cerevisiae*. *J. Biol. Chem.* 275, 5431–5440 CrossRef Medline

64. Bozaquel-Morais, B. L., Madeira, J. B., Venâncio, T. M., Pacheco-Rosa, T., Masuda, C. A., and Montero-Lomeli, M. (2017) A chemogenomic screen reveals novel Snf1p/AMPK independent regulators of acetyl-CoA carboxylase. *PLoS One* 12, e0169682 CrossRef Medline

65. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25, 402–408 CrossRef Medline

66. Hoffman, C. S., and Winston, F. (1987) A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of *Escherichia coli*. *Gene* 57, 267–272 CrossRef Medline

67. Torelli, N. Q., Ferreira-Júnior, J. R., Kowaltowski, A. J., and da Cunha, F. M. (2018) Enoxacin extends lifespan of *Caenorhabditis elegans* by inhibiting miR-34–5p and promoting mitohormesis. *Redox Biol.* 18, 84–92 CrossRef Medline